Despite solid data, the lack of high-value indications and no unique platform makes Nuvalent's valuation seem inflated; I ...

The FDA is evaluating a new drug application for taletrectinib in patients with ROS1 fusion–positive non–small cell lung ...

Cullinan Therapeutics rebranded from oncology to immunology+oncology, focusing on CD19 TCEs for autoimmune diseases. Check ...

Oral and poster presentations of its DZD8586 study results in chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL) are selected by ASCO Scientific Program Committee. In ...

Akeso Inc. (9926.HK) ("Akeso", "the Company") released its 2024 annual report, emphasizing the company's key achievements in drug research, clinical development, and commercialization.

The TKI zongertinib is currently being reviewed by the FDA for a potential approval for patients with HER2 mutation–positive ...

“Right now, only 20% of patients with EGFR-positive NSCLC survive beyond five years,” explained Joshua Bauml, vice president, ...

Olverembatinib (HQP1351), a novel, next-generation TKI and the first third-generation BCR-ABL1 TKI, has been approved in ...

Stephanie is a professional finance and small business writer with more than a decade of experience. Her work has been featured on a variety of top finance sites, including The Penny Hoarder ...

T790M is an EGFR mutation seen in about two-thirds of all drug-resistant NSCLC cases. The mutation causes a change in the amino acids, which affects how someone will respond to therapy.

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Finding one of the best cheap cell phone plans no longer means sacrificing data just to ...

The first-line combination of amivantamab-vmjw plus lazertinib extended OS compared with osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer, according to data from the ...